Enter your email address
Submit
Write your message
International Journal of Medical Laboratory
Shahid Sadoughi University of Medical Sciences
Fri, Dec 27, 2024
[Archive]
Volume 7, Issue 1 (February 2020)
IJML 2020, 7(1): 30-34 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Daneshdoust D, Qujeq D, Vakili Sadeghi M, Mahmoudi A, Ghasmtabar H. Measurement of Serum Survivin to Discriminate Patients with Breast Cancer from Normal Subjects. IJML 2020; 7 (1) :30-34
URL: http://ijml.ssu.ac.ir/article-1-320-en.html
URL: http://ijml.ssu.ac.ir/article-1-320-en.html
2Cellular and Molecular Biology Research Center (CMBRC), Health Research Institute, Babol University of Medical Sciences, Babol, Iran. 3Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran. 4Dental Materials Research Center, Institute of Health, Babol University of Medical Sciences, Babol, Iran. 5Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Abstract: (1340 Views)
Background and Aims: There is now an increasing body of evidence that survivin is a protein, expressed highly in breast cancer. The signaling interaction of protein survivin in breast cancer is still unclear, but physiological regulation of survivin seems to be linked to the breast cancer occurrence and severity of it.
Materials and Methods: Serum samples were obtained from April 2015 to November 2017 out of women enrolled in a group undergoing annual breast cancer testing. Routine blood samples were analyzed at the Biochemical Laboratory of Rouhani Babol University Hospital .
Results: Serum levels of survivin in patients with breast cancer group increased compared to the healthy controls [207.520±110.284 (mean±SD) vs. 126.212±53.130, ng/L, p<0.001]. Also, we detected a positive correlation between elevated serum survivin level and clinical characteristics of patients with breast cancer.
Conclusions: Serum survivin measurement was shown to discriminate patients with breast cancer from healthy controls. However, further studies are needed to confirm this role and its benefits.
Materials and Methods: Serum samples were obtained from April 2015 to November 2017 out of women enrolled in a group undergoing annual breast cancer testing. Routine blood samples were analyzed at the Biochemical Laboratory of Rouhani Babol University Hospital .
Results: Serum levels of survivin in patients with breast cancer group increased compared to the healthy controls [207.520±110.284 (mean±SD) vs. 126.212±53.130, ng/L, p<0.001]. Also, we detected a positive correlation between elevated serum survivin level and clinical characteristics of patients with breast cancer.
Conclusions: Serum survivin measurement was shown to discriminate patients with breast cancer from healthy controls. However, further studies are needed to confirm this role and its benefits.
Type of Study: Research |
Subject:
Biochemistry
Received: 2019/06/11 | Accepted: 2019/11/27 | Published: 2020/01/30
Received: 2019/06/11 | Accepted: 2019/11/27 | Published: 2020/01/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
